financetom
Business
financetom
/
Business
/
What's Going On With Abercrombie & Fitch Company Stock Today?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Abercrombie & Fitch Company Stock Today?
Aug 27, 2025 7:26 AM

Abercrombie & Fitch Company ( ANF ) shares were trading lower in the premarket on Wednesday.

The company reported second-quarter adjusted earnings per share of $2.32, beating the analyst consensus estimate of $2.30.

Quarterly sales of $1.209 billion (+7% year over year) outpaced the Street view of $1.195 billion.

Also Read: Kohl’s Raises Outlook After Sephora Rollout

The company stated that Hollister brands delivered their “best ever” second-quarter net sales, posting growth of 19%. In contrast, Abercrombie brands reported a 5% decline.

Abercrombie & Fitch’s net sales growth was driven by an 8% increase in the Americas and a 12% increase in APAC, partially offset by a 1% decline in EMEA.

The company reported an operating margin of 17.1% as a percentage of sales on a reported basis and 13.9% on an adjusted basis, compared to 15.5% in the prior year.

“While we made progress on key inventory initiatives by leveraging promotions and testing new product concepts, Abercrombie brands net sales were down 5%, lapping 26% growth in the prior year,” said CEO Fran Horowitz. “On the bottom line, we exceeded our second quarter profitability expectations, while also returning $50 million to shareholders through our sixth consecutive quarter of share repurchases.”

The company exited the quarter with cash and equivalents worth $573 million.

Inventories stood at $593 million compared to $575 million as of February 1, 2025. They were $540 million as of August 3, 2024.

Outlook

“We entered the second half of 2025 on offense,” Horowitz said.

The company raised its fiscal year 2025 GAAP earnings per share guidance from a prior range of $9.50 to $10.50 to a new range of $10.00 to $10.50, compared to the previous estimate of $10.28. It also lifted its fiscal year 2025 sales guidance from a range of $5.100 billion to $5.250 billion to a new range of $5.200 billion to $5.290 billion, versus the $5.205 billion estimate.

“Our team remains focused on delivering for our customers while investing to capitalize on the significant, long-term opportunities for our global brands,” Horowitz added.

Abercrombie & Fitch ( ANF ) said it expects third-quarter 2025 GAAP earnings per share to be in the range of $2.05 to $2.25, below the $2.55 estimate.

The company forecasted sales of $1.270 billion to $1.290 billion, compared to the previously estimated $1.261 billion.

Price Action: ANF shares are trading up 1.30% at $98.00 as of the last check on Wednesday.

Read Next:

Alibaba Unites Its Empire To Fight Back Against Meituan

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cineplex Swings to Q2 Loss as Revenue, Theater Attendance Drop
Cineplex Swings to Q2 Loss as Revenue, Theater Attendance Drop
Aug 9, 2024
07:31 AM EDT, 08/09/2024 (MT Newswires) -- Cineplex ( CPXGF ) said Friday that it swung to a net loss in the second quarter following a 25% drop in revenue. The movie theater operator booked a net loss of $21.4 million, or $0.33 per share, compared to a net profit of $176.5 million, or $2.79 per share. Revenue dropped to...
Evercore hires Goldman banker Kamo for private equity dealmaking, sources say
Evercore hires Goldman banker Kamo for private equity dealmaking, sources say
Aug 9, 2024
NEW YORK, Aug 9 (Reuters) - Investment bank Evercore ( EVR ) has hired a top Goldman Sachs ( GS ) dealmaker as a senior managing director to help drive its coverage of private equity firms and alternative asset managers, people familiar with the matter said on Friday. David Kamo, who was named global head of dealmaking for financial sponsors...
Merck to Acquire B-Cell Depletion Therapy From Curon Biopharmaceutical
Merck to Acquire B-Cell Depletion Therapy From Curon Biopharmaceutical
Aug 9, 2024
07:24 AM EDT, 08/09/2024 (MT Newswires) -- Merck ( MRK ) said Friday it has agreed to acquire full global rights to CN201, an investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from Curon Biopharmaceutical. Under the terms of the agreement, Merck ( MRK ) will pay $700 million upfront in cash and Curon will be eligible...
Evolent Health Q2 Adjusted Earnings, Revenue Climb; Lifts Lower End of FY Revenue Guidance
Evolent Health Q2 Adjusted Earnings, Revenue Climb; Lifts Lower End of FY Revenue Guidance
Aug 9, 2024
07:16 AM EDT, 08/09/2024 (MT Newswires) -- Evolent Health ( EVH ) reported Q2 adjusted earnings Friday of $0.30 per share, up from $0.14 a year earlier. Analysts polled by Capital IQ expected $0.25. Revenue for the quarter ended June 30 was $647.1 million, up from $469.1 million a year earlier. Analysts polled by Capital IQ expected $636.4 million. Evolent...
Copyright 2023-2026 - www.financetom.com All Rights Reserved